您好,欢迎来到科研在线!科研采购 · 选型 · 实验方法
首页产品库品牌馆产品类别品牌新闻会议会展产品试用求职招聘资讯专题教程
PRO / Antibodies

Anti-Human PD1 (Pembrolizumab Biosimilar)

Anti-Human PD1 (Pembrolizumab Biosimilar)

英诺赛图(InnoCyto)的 Anti-Human PD1 (Pembrolizumab Biosimilar)(克隆 Pembrolizumab) 为人源 IgG4 抗体,靶向 PD1(别名 PD-1 等),适用于流式细胞术。提供 1 mg、5 mg、20 mg 规格,目录价 ¥1,288 起,仅供科研使用(RUO)。

生物试剂 供应商 上海英诺赛图 ↗ 型号 504701 更新 2026-11-12
参考价格区间
¥1,288
含税参考价,实际以配置与渠道报价为准
本条目供应商 上海英诺赛图原厂 1865个条目 进入企业主页

01产品图片

02产品简介

英诺赛图(InnoCyto)的 Anti-Human PD1 (Pembrolizumab Biosimilar)(克隆 Pembrolizumab) 为人源 IgG4 抗体,靶向 PD1(别名 PD-1 等),适用于流式细胞术。提供 1 mg、5 mg、20 mg 规格,目录价 ¥1,288 起,仅供科研使用(RUO)。

03产品介绍

规格与货号

504701 | 1 mg | ¥1,288

504702 | 5 mg | ¥4,000

504703 | 20 mg | ¥7,458

Product Details

Product Description|Anti-Human PD-1 (Pembrolizumab Biosimilar)

Regulatory Status|RUO

Species specificity|Human

Storage Conditions|4ºC

Maximal Shelf Life|12 months

See All Formats|Clone Pembrolizumab

Background Information

Pembrolizumab is a fully humanized monoclonal antibody of the immunoglobulin G4 kappa (IgG4κ) subclass engineered to specifically bind to the programmed death-1 (PD-1, also known as CD279) receptor expressed on activated T cells. Structurally, Pembrolizumab is a glycoprotein with a molecular weight of approximately 149 kilodaltons (kDa). The molecule consists of two identical heavy chains and two identical light chains joined by disulfide bonds, forming the characteristic Y-shaped architecture typical of immunoglobulins. Each heavy chain is composed of one variable (VH) and three constant (CH1-CH3) domains, while each light chain contains one variable (VL) and one constant (CL) domain. It is produced in mammalian expression systems, such as Chinese Hamster Ovary (CHO) cells, to ensure correct folding, glycosylation, and molecular stability.

The variable domains of Pembrolizumab contain complementarity-determining regions (CDRs) that form the antigen-binding sites responsible for recognizing a specific epitope on the PD-1 receptor. These CDRs establish high-affinity, non-covalent interactions with the extracellular domain of PD-1. By occupying the ligand-binding region of PD-1, Pembrolizumab effectively blocks its interaction with programmed death-ligand 1 (PD-L1) and programmed death-ligand 2 (PD-L2). This blockade inhibits the intracellular signaling cascade initiated by PD-1 engagement, which normally leads to suppression of T-cell activation, cytokine production, and proliferation. In experimental systems, this results in enhanced T-cell signaling and immune response regulation.

The Fc (fragment crystallizable) region of Pembrolizumab is derived from the IgG4 isotype and includes an engineered S228P mutation in the hinge region to improve structural integrity by preventing half-antibody exchange. The IgG4 Fc configuration minimizes binding to Fc gamma receptors (FcγRs) and complement component C1q, thus greatly reducing antibody-dependent and complement-mediated cytotoxicity. Overall, Pembrolizumab exemplifies advanced antibody engineering, combining high receptor specificity, precise inhibitory activity, and optimized molecular stability for studies of immune checkpoint regulation and T-cell receptor–ligand dynamics.

Data Sheets

Cat # Size Price Quantity 5047011 mg Add to Cart5047025 mg Add to Cart50470320 mg Add to Cart

04完整参数表

参数由厂商资料整理,采购前请以最终报价单与技术协议为准。

包装规格1 mg
ClonePembrolizumab
ApplicationFlow cytometry, animal model study
Host SpeciesMammalian cells
ReactivityHuman
FormatLiquid
Product DescriptionAnti-Human PD-1 (Pembrolizumab Biosimilar)
IsotypeHuman IgG4
Regulatory StatusRUO
ClonalityRecombinant
ImmunogenHuman PD1
Species specificityHuman
Purity>95% by reducing SDS-PAGE
GradeIn vivo
Storage Conditions4ºC
SynonymsCD279
RRIDAB_3739323
Target NamePD1, PD-1, PDCD1, CD279, SLEB2
Antibody TypeRecombinant
目录价¥1,288

05荣誉与资质

该品牌暂未上传荣誉证书与资质文件。以下是平台可核验的公开信息,未上传项如实标注,不做推断。

  • 营业执照未上传
  • 品牌授权未上传
  • 产品检测报告未上传
会员身份
收费会员
经营身份
原厂
成立年份
2020 年
所在地
上海
收录条目
1865 个
平台核验
平台代管
向品牌方索取资质文件

06品牌与供应商

上海英诺赛图 原厂
InnoCyto

以可信赖的细胞研究试剂,助力科研突破

进入企业主页
1865 本目录条目
产地 / 总部上海市浦东新区
成立年份2020 年
本目录主营生化试剂 / 蛋白与抗体

InnoCyto(上海英诺赛图生物科技有限公司)致力于通过开发高质量细胞分析试剂,加速科学发现进程。公司为研究人员提供细胞层面探索所需的工具,推动免疫学、肿瘤学等多领域的研究创新。 核心团队拥有丰富的行业经验,曾参与全球头部生命科学公司的标杆项目搭建,深刻理解工业界与学术研究的前沿需求。试剂从设计之初即以精确性、一致性、高性能为核心标准,让科学家能把精力集中在最核心的研究工作上。 公司将深厚的科学积累与对品质的严格承诺相结合,力争成为全球研究人员信赖的合作伙伴。产品线覆盖经验证的一抗与二抗、同型对照、生物类似药抗体、重组蛋白、细胞因子、免疫检测试剂盒及配套试剂,并提供重组蛋白/抗体表达与标记偶联服务。

售后与服务

品牌资料由厂商公开信息与授权渠道核对整理;条目参数与价格以最终报价单为准。

引用此条目 产品目录 · 更新于 2026-11-12
科研在线(TeleVM). Anti-Human PD1 (Pembrolizumab Biosimilar)(504701)[EB/OL]. 产品目录, 2026-11-12. https://www.suprotek.cn/products/item/anti-human-pd1-pembrolizumab-biosimilar.html.
TeleVM. (2026, November 12). Anti-Human PD1 (Pembrolizumab Biosimilar)(504701). 产品目录. https://www.suprotek.cn/products/item/anti-human-pd1-pembrolizumab-biosimilar.html
@misc{biocsp_item_anti_human_pd1_pembrolizumab_biosimilar,
  title        = {Anti-Human PD1 (Pembrolizumab Biosimilar)(504701)},
  author       = {{科研在线}},
  year         = {2026},
  howpublished = {产品目录},
  note         = {更新于 2026-11-12,产品目录},
  url          = {https://www.suprotek.cn/products/item/anti-human-pd1-pembrolizumab-biosimilar.html}
}

GB/T 7714 用于中文论文与报告;APA 7 用于英文期刊;BibTeX 可直接导入 Zotero、EndNote 或 LaTeX。

许可:CC BY-NC 4.0 · 转载注明来源
获取正式报价

Anti-Human PD1 (Pembrolizumab Biosimilar)

提交后由平台转给品牌方,通常 1 个工作日内联系。不需要注册。